Home > In process > Circulating cytokine levels and 5-year vascular recurrence after stroke: A multicenter prospective cohort study. > print

001     285005
005     20260202114302.0
024 7 _ |a 10.1093/esj/23969873251360145
|2 doi
024 7 _ |a pmid:41614521
|2 pmid
024 7 _ |a 2396-9873
|2 ISSN
024 7 _ |a 2396-9881
|2 ISSN
037 _ _ |a DZNE-2026-00139
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Zhang, Lanyue
|0 0000-0002-6798-1320
|b 0
245 _ _ |a Circulating cytokine levels and 5-year vascular recurrence after stroke: A multicenter prospective cohort study.
260 _ _ |a London
|c 2026
|b Sage Publishing
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1770028301_15531
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Anti-inflammatory therapies are tested in randomized trials for secondary stroke prevention. Detecting inflammatory biomarkers that predict vascular recurrence could optimize patient selection for these trials.In a multicenter prospective cohort study, we measured plasma levels of 22 inflammatory cytokines in 486 acute stroke patients (474 ischemic strokes and 12 intracerebral hemorrhages; median age 68 years, 34% female, median 3 days post-stroke onset). Patients were followed for over 5 years through telephone and in-person interviews to record the occurrence of the following outcomes: (1) recurrent stroke or transient ischemic attack (TIA; primary outcome); (2) a composite of recurrent vascular events (stroke, TIA, acute coronary syndrome, hospital admission due to heart failure, and death; secondary outcome). Associations between cytokine levels and these outcomes were analyzed using Cox proportional hazards models adjusted for demographic and vascular risk factors.During the 5-year follow-up period, 59 patients (12.1%) experienced recurrent stroke or TIA, and 118 (24.3%) experienced recurrent vascular events. After adjustments for demographic and vascular risk factors, and correction for multiple comparisons, higher plasma levels of CD62E (adjusted Hazard Ratio (aHR)/SD increment: 1.63, 95%CI 1.22-2.20) and MIF (aHR: 1.56, 95%CI 1.18-2.06) in the acute phase after stroke were statistically significantly associated with increased risk of recurrent stroke or TIA. The associations followed a dose-response pattern across quartiles of CD62E and MIF levels. Adding baseline CD62E and MIF levels to models including age, sex, vascular risk factors, and baseline C-reactive protein (CRP) levels led to significant improvements in the prediction of 5-year risk of recurrent stroke or TIA (ΔC-index 0.030-0.050).Among stroke patients, higher baseline levels of CD62E and MIF improved prediction of 5-year risk of recurrent stroke or TIA on top of vascular risk factors and CRP levels. Whether assessment of these cytokines could improve patient selection for secondary prevention trials of anti-inflammatory treatments, should be explored in future studies.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Stroke
|2 Other
650 _ 7 |a cytokines
|2 Other
650 _ 7 |a inflammation
|2 Other
650 _ 7 |a recurrence
|2 Other
650 _ 7 |a risk prediction
|2 Other
650 _ 7 |a Cytokines
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Recurrence
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Cytokines: blood
|2 MeSH
650 _ 2 |a Ischemic Attack, Transient: blood
|2 MeSH
650 _ 2 |a Biomarkers: blood
|2 MeSH
650 _ 2 |a Stroke: blood
|2 MeSH
650 _ 2 |a Follow-Up Studies
|2 MeSH
650 _ 2 |a Risk Factors
|2 MeSH
650 _ 2 |a Ischemic Stroke: blood
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
700 1 _ |a Antabi, Mohamad Ali
|b 1
700 1 _ |a Mattar, Jana
|b 2
700 1 _ |a El Bounkari, Omar
|b 3
700 1 _ |a Fang, Rong
|0 0000-0002-5663-9407
|b 4
700 1 _ |a Waegemann, Karin
|0 P:(DE-2719)2814124
|b 5
|u dzne
700 1 _ |a Bode, Felix J
|0 P:(DE-2719)2811949
|b 6
700 1 _ |a Stösser, Sebastian
|0 P:(DE-2719)9000778
|b 7
|u dzne
700 1 _ |a Hermann, Peter
|0 P:(DE-2719)2812183
|b 8
700 1 _ |a Liman, Thomas G
|0 P:(DE-2719)9000189
|b 9
|u dzne
700 1 _ |a Nolte, Christian
|0 P:(DE-2719)9000234
|b 10
700 1 _ |a Ikenberg, Benno
|b 11
700 1 _ |a Bernkopf, Kathleen
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Petzold, Gabor C
|0 P:(DE-2719)2810273
|b 13
|u dzne
700 1 _ |a Bernhagen, Jürgen
|b 14
700 1 _ |a Dichgans, Martin
|0 P:(DE-2719)2000030
|b 15
700 1 _ |a Georgakis, Marios K
|0 0000-0003-3507-3659
|b 16
700 1 _ |a Investigators, DEMDAS
|b 17
|e Collaboration Author
700 1 _ |a Endres, Matthias
|0 P:(DE-2719)2811033
|b 18
|e Contributor
|u dzne
700 1 _ |a Düzel, Emrah
|0 P:(DE-2719)2000005
|b 19
|e Contributor
|u dzne
700 1 _ |a Kerti, Lucia
|0 P:(DE-2719)2811628
|b 20
|e Contributor
|u dzne
700 1 _ |a Neumann, Katja
|0 P:(DE-2719)2810407
|b 21
|e Contributor
|u dzne
700 1 _ |a Meißner, Julius N
|b 22
|e Contributor
700 1 _ |a Liman, Thomas G.
|0 P:(DE-2719)9000189
|b 23
|e Contributor
|u dzne
700 1 _ |a Kerti, Lucia
|0 P:(DE-2719)2811628
|b 24
|e Contributor
|u dzne
700 1 _ |a Nolte, Christian H
|0 P:(DE-2719)9000234
|b 25
|e Contributor
700 1 _ |a Wittenberg, Tatjana
|b 26
|e Contributor
700 1 _ |a Scheitz, Jan F
|0 P:(DE-2719)9001514
|b 27
|e Contributor
700 1 _ |a Prüß, Harald
|0 P:(DE-2719)2810931
|b 28
|e Contributor
|u dzne
700 1 _ |a Sperber, Pia Sophie
|b 29
|e Contributor
700 1 _ |a Nave, Alexander H
|b 30
|e Contributor
700 1 _ |a Kufner Ibaroule, Anna
|b 31
|e Contributor
700 1 _ |a Petzold, Gabor C
|0 P:(DE-2719)2810273
|b 32
|e Contributor
|u dzne
700 1 _ |a Bode, Felix
|0 P:(DE-2719)2811949
|b 33
|e Contributor
|u dzne
700 1 _ |a Stösser, Sebastian
|0 P:(DE-2719)9000778
|b 34
|e Contributor
|u dzne
700 1 _ |a Meissner, Julius
|b 35
|e Contributor
700 1 _ |a Ebrahimi, Taraneh
|0 P:(DE-2719)9003076
|b 36
|e Contributor
|u dzne
700 1 _ |a Nordsiek, Julia
|b 37
|e Contributor
700 1 _ |a Beckonert, Niklas
|0 P:(DE-2719)9002283
|b 38
|e Contributor
|u dzne
700 1 _ |a Kindler, Christine
|0 P:(DE-2719)9000373
|b 39
|e Contributor
|u dzne
700 1 _ |a Zerr, Inga
|0 P:(DE-2719)2000058
|b 40
|e Contributor
|u dzne
700 1 _ |a Hermann, Peter
|0 P:(DE-2719)2812183
|b 41
|e Contributor
700 1 _ |a Schmitz, Matthias
|0 P:(DE-2719)9000287
|b 42
|e Contributor
|u dzne
700 1 _ |a Goebel, Stefan
|0 P:(DE-2719)9001986
|b 43
|e Contributor
700 1 _ |a Bunck, Timothy
|b 44
|e Contributor
700 1 _ |a Schütte-Schmidt, Julia
|b 45
|e Contributor
700 1 _ |a Nuhn, Sabine
|b 46
|e Contributor
700 1 _ |a Volpers, Corinna
|b 47
|e Contributor
700 1 _ |a Dechent, Peter
|b 48
|e Contributor
700 1 _ |a Bähr, Mathias
|0 P:(DE-2719)2811350
|b 49
|e Contributor
|u dzne
700 1 _ |a Görtler, Michael
|0 P:(DE-2719)2811292
|b 50
|e Contributor
700 1 _ |a Glanz, Wenzel
|0 P:(DE-2719)2811614
|b 51
|e Contributor
|u dzne
700 1 _ |a Perosa, Valentina
|0 P:(DE-2719)9000985
|b 52
|e Contributor
700 1 _ |a Dichgans, Martin
|0 P:(DE-2719)2000030
|b 53
|e Contributor
|u dzne
700 1 _ |a Wollenweber, Frank
|b 54
|e Contributor
700 1 _ |a Georgakis, Marios
|b 55
|e Contributor
700 1 _ |a Fang, Rong
|b 56
|e Contributor
700 1 _ |a Janowitz, Daniel
|0 P:(DE-2719)9002557
|b 57
|e Contributor
|u dzne
700 1 _ |a Waegemann, Karin
|0 P:(DE-2719)2814124
|b 58
|e Contributor
|u dzne
700 1 _ |a Tiedt, Steffen
|b 59
|e Contributor
700 1 _ |a Wunderlich, Silke
|b 60
|e Contributor
700 1 _ |a Ikenberg, Benno
|b 61
|e Contributor
700 1 _ |a Bernkopf, Kathleen
|b 62
|e Contributor
700 1 _ |a Huber, Christiane
|b 63
|e Contributor
700 1 _ |a Poppert, Holger
|b 64
|e Contributor
700 1 _ |a Düring, Marco
|0 P:(DE-2719)9000062
|b 65
|e Contributor
700 1 _ |a Araque Caballero, Miguel Ángel
|0 P:(DE-2719)2812570
|b 66
|e Contributor
700 1 _ |a Gesierich, Benno
|0 P:(DE-2719)9001112
|b 67
|e Contributor
|u dzne
700 1 _ |a Dewenter, Anna
|b 68
|e Contributor
700 1 _ |a Dobisch, Laura
|0 P:(DE-2719)2811611
|b 69
|e Contributor
|u dzne
700 1 _ |a Neumann, Katja
|0 P:(DE-2719)2810407
|b 70
|e Contributor
|u dzne
700 1 _ |a Speck, Oliver
|0 P:(DE-2719)2810706
|b 71
|e Contributor
|u dzne
700 1 _ |a Spottke, Annika
|0 P:(DE-2719)2811324
|b 72
|e Contributor
|u dzne
700 1 _ |a Stöcker, Tony
|0 P:(DE-2719)2810538
|b 73
|e Contributor
|u dzne
700 1 _ |a Bartenstein, Peter
|b 74
|e Contributor
700 1 _ |a Wagner, Michael
|0 P:(DE-2719)2000057
|b 75
|e Contributor
|u dzne
773 _ _ |a 10.1093/esj/23969873251360145
|g Vol. 11, no. 1, p. 23969873251360145
|0 PERI:(DE-600)2851287-X
|n 1
|p 23969873251360145
|t European stroke journal
|v 11
|y 2026
|x 2396-9873
856 4 _ |u https://pub.dzne.de/record/285005/files/DZNE-2026-00139_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/285005/files/DZNE-2026-00139_Restricted.pdf?subformat=pdfa
|x pdfa
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2814124
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2811949
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)9000778
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2812183
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)9000189
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)9000234
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2810273
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 P:(DE-2719)2000030
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 18
|6 P:(DE-2719)2811033
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 19
|6 P:(DE-2719)2000005
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 20
|6 P:(DE-2719)2811628
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 21
|6 P:(DE-2719)2810407
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 23
|6 P:(DE-2719)9000189
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 24
|6 P:(DE-2719)2811628
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 28
|6 P:(DE-2719)2810931
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 32
|6 P:(DE-2719)2810273
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 33
|6 P:(DE-2719)2811949
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 34
|6 P:(DE-2719)9000778
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 36
|6 P:(DE-2719)9003076
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 38
|6 P:(DE-2719)9002283
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 39
|6 P:(DE-2719)9000373
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 40
|6 P:(DE-2719)2000058
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 42
|6 P:(DE-2719)9000287
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 49
|6 P:(DE-2719)2811350
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 51
|6 P:(DE-2719)2811614
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 53
|6 P:(DE-2719)2000030
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 57
|6 P:(DE-2719)9002557
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 58
|6 P:(DE-2719)2814124
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 67
|6 P:(DE-2719)9001112
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 69
|6 P:(DE-2719)2811611
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 70
|6 P:(DE-2719)2810407
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 71
|6 P:(DE-2719)2810706
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 72
|6 P:(DE-2719)2811324
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 73
|6 P:(DE-2719)2810538
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 75
|6 P:(DE-2719)2000057
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2025-11-07
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR STROKE J : 2022
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-07
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-07
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EUR STROKE J : 2022
|d 2025-11-07
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 0
920 1 _ |0 I:(DE-2719)1013020
|k AG Petzold
|l Vascular Neurology
|x 1
920 1 _ |0 I:(DE-2719)1011001
|k Clinical Research (Bonn)
|l Clinical Research Coordination
|x 2
920 1 _ |0 I:(DE-2719)1811005
|k AG Endres
|l Interdisciplinary Dementia Research
|x 3
920 1 _ |0 I:(DE-2719)5000022
|k AG Dichgans
|l Vascular Cognitive Impairment & Post-Stroke Dementia
|x 4
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)1013020
980 _ _ |a I:(DE-2719)1011001
980 _ _ |a I:(DE-2719)1811005
980 _ _ |a I:(DE-2719)5000022
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21